ReviewFrontiers in immunology2026
Extracellular vesicles as vaccine platforms: emerging opportunities for malaria.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria is the deadliest parasitic disease worldwide, and the urgent need for preventive strategies remains unmet. The parasite poses unique challenges, as it exhibits remarkable epitope variability and undergoes genetic mutations that allow adaptation to control measures, including drug treatment, and high ability of immune system evasion. In addition, malaria frequently develops asymptomatic forms, which sustain silent transmission and perpetuate the disease burden. In this complex context, extracellular vesicles (EVs) have emerged as promising tools for vaccine development. EVs can be engineered to carry specific and various antigens and to exploit their natural ability to fuse with cell membranes, enabling effective delivery. Depending on their cargo, they can modulate immune responses in a tailored manner, reawakening host immunity and targeting the parasite even in dormant stages. Despite extensive advances in EV-based approaches for viral and cancer models, their application to neglected diseases, including malaria, remains limited. This review aims to discuss strategies for engineering EVs as vaccines, drawing on insights from other disease models and highlighting the unique features of malaria that could benefit from such an approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.